MiR-128 plays a role in modulating chemotherapeutic sensitivity in cancer stem cells by targeting Bmi-1 and Musashi-1, and when MiR-128 expression is lowered in cancer tissue it involves with chemotherapeutic resistance [19] BMI1 is a proto-oncogene and a part of the polycomb group complex. It plays a role in DNA damage repair and is a factor in resistance to chemotherapies [23]. On the other hand, Musashi-1 is an RNA binding protein controlling expression of target RNAs [24]. With the use of BRM270 it will lead to an increase in the expression of miR-128 by 2-3 folds in a lung adenocarcinoma cell like A549. It basically blocks activation of NF-kB and this leads to inhibiting miR-21 expression which is involved in resistance to chemotherapeutic agents like gefitinib and this will then result in lowering proliferation in A549 cells [19].
Recent comments